Amneal Pharmaceuticals Overview
- Year Founded
-
2002
- Status
-
Public
- Employees
-
8,500
- Stock Symbol
-
AMRX
- Investments
-
19
- Share Price
-
$21.37
- (As of Friday Closing)
Amneal Pharmaceuticals General Information
Description
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Contact Information
Website
www.amneal.comCorporate Office
- 400 Crossing Boulevard
- 3rd Floor
- Bridgewater, NJ 08807
- United States
Corporate Office
- 400 Crossing Boulevard
- 3rd Floor
- Bridgewater, NJ 08807
- United States
Amneal Pharmaceuticals Timeline
Amneal Pharmaceuticals Stock Performance
As of 13-Nov-2026, Amneal Pharmaceuticals’s stock price is $21.37. Its current market cap is $7.45B with 348M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $21.37 | $21.70 | $11.39 - $22.07 | $7.45B | 348M | 3.12M | $0.41 |
Amneal Pharmaceuticals Financials Summary
As of 30-Sep-2026, Amneal Pharmaceuticals has a trailing 12-month revenue of $3.2B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 9,179,868 | 6,512,731 | 5,084,375 | 4,439,002 |
| Revenue | 3,195,719 | 3,018,760 | 2,793,957 | 2,393,607 |
| EBITDA | 638,489 | 603,900 | 439,782 | 399,759 |
| Net Income | 133,299 | 72,057 | (116,886) | (83,993) |
| Total Assets | 5,267,221 | 3,678,280 | 3,501,445 | 3,472,569 |
| Total Debt | 3,282,895 | 2,689,046 | 2,593,139 | 2,750,523 |
Amneal Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Amneal Pharmaceuticals Comparisons
Industry
Financing
Details
Amneal Pharmaceuticals Competitors (59)
One of Amneal Pharmaceuticals’s 59 competitors is Glenmark Pharmaceuticals, a Corporation company based in Mumbai, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Glenmark Pharmaceuticals | Corporation | Mumbai, India | ||||
| Zydus Lifesciences | Corporation | Ahmedabad, India | ||||
| Pil-psychotropics India | Corporation | Faridabad, India | ||||
| Alkem Laboratories | Formerly PE-Backed | Mumbai, India | ||||
| Viatris | Corporation | Canonsburg, PA |
Amneal Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Amneal Pharmaceuticals Patents
Amneal Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026217441-A2 | Method for treating sleep issues in parkinson's disease patients | Pending | 07-Apr-2025 | ||
| WO-2026128848-A1 | Levodopa dosing regimen | Pending | 13-Dec-2024 | ||
| US-20250345266-A1 | Ready-to-infuse oxytocin compositions | Pending | 08-May-2024 | ||
| WO-2025235701-A1 | Ready-to-infuse oxytocin compositions | Pending | 08-May-2024 | ||
| WO-2025226771-A1 | Immunosuppressive dosage forms and methods of use | Pending | 24-Apr-2024 | A61P37/06 |
Amneal Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Amneal Pharmaceuticals Investments & Acquisitions (19)
Amneal Pharmaceuticals’s most recent deal was a Merger/Acquisition with Kashiv BioSciences for . The deal was made on 10-Aug-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Kashiv BioSciences | 10-Aug-2026 | Merger/Acquisition | Drug Delivery | ||
| Saol Therapeutics (Baclofen Franchise, Lioresal and Lyvispahtm) | 05-Jan-2022 | Corporate Asset Purchase | Buildings and Property | ||
| Puniska Healthcare | 02-Nov-2021 | Merger/Acquisition | Pharmaceuticals | ||
| Kashiv Specialty | 02-Apr-2021 | Merger/Acquisition | Drug Discovery | ||
| AvKARE | 31-Jan-2020 | Merger/Acquisition | Pharmaceuticals |
Amneal Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
34.24 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Amneal Pharmaceuticals Exits (2)
Amneal Pharmaceuticals’s most recent exit was on 01-Jun-2013 from Creo Pharma. The exit was categorized as with 3 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Creo Pharma | 01-Jun-2013 | Completed |
|
||
| Exeltis USA Dermatology | 07-Dec-2010 | Merger/Acquisition | Completed |
|
Amneal Pharmaceuticals Affiliates
Subsidiaries (4)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Puniska Healthcare | Ahmedabad, India | 2017 | |
| Amneal-Agila | Bridgewater, NJ | 2012 | |
| Kashiv BioSciences | Piscataway, NJ | 2010 | |
| AvKARE | Pulaski, TN | 2007 |
Amneal Pharmaceuticals FAQs
-
When was Amneal Pharmaceuticals founded?
Amneal Pharmaceuticals was founded in 2002.
-
Where is Amneal Pharmaceuticals headquartered?
Amneal Pharmaceuticals is headquartered in Bridgewater, NJ.
-
What is the size of Amneal Pharmaceuticals?
Amneal Pharmaceuticals has 8,500 total employees.
-
What industry is Amneal Pharmaceuticals in?
Amneal Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Amneal Pharmaceuticals a private or public company?
Amneal Pharmaceuticals is a Public company.
-
What is Amneal Pharmaceuticals’s stock symbol?
The ticker symbol for Amneal Pharmaceuticals is AMRX.
-
What is the current stock price of Amneal Pharmaceuticals?
As of 13-Nov-2026 the stock price of Amneal Pharmaceuticals is $21.37.
-
What is the current market cap of Amneal Pharmaceuticals?
The current market capitalization of Amneal Pharmaceuticals is $7.45B.
-
What is Amneal Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Amneal Pharmaceuticals is $3.2B.
-
Who are Amneal Pharmaceuticals’s competitors?
Glenmark Pharmaceuticals, Zydus Lifesciences, Pil-psychotropics India, Alkem Laboratories, and Viatris are some of the 59 competitors of Amneal Pharmaceuticals.
-
What is Amneal Pharmaceuticals’s annual earnings per share (EPS)?
Amneal Pharmaceuticals’s EPS for 12 months was $0.41.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
